Eli Lilly stock analysis
Eli Lilly passes 7 of 8 fundamental tests, a score of 9/10. On the daily chart it is in an uptrend, RSI 69, 3% below its 52-week high: uptrend, no fresh entry: wait for a pullback or breakout. Its own volatility puts the likely range at $1,138–$1,388 a month from now and $891.18–$1,773 in a year (68% bands). The last two days of news lean bullish (2 positive, 1 negative stories).
Fundamentals 9/10
- Market cap
- $1120.9 B
- P/E · forward
- 42.2 · 26.6
- PEG · P/B
- 1.2 · 33.1
- ROE · net margin
- +102% · +34%
- Revenue · earnings growth
- +48% · +26%
- Debt / equity
- 162%
- Dividend · beta
- 0.5% · 0.5
- Next results
- 29 Oct 2026
- ✓ ROE above 15%
- ✓ Net margin above 10%
- ✓ Revenue growing over 10%
- ✓ Earnings growing
- ✕ Debt/equity under 100%
- ✓ Positive free cash flow
- ✓ Forward P/E under trailing (earnings expected up)
- ✓ PEG under 2
Swing technicals (daily)
- Trend
- up · 50d above 200d
- RSI(14)
- 69
- 20 / 50 / 200-day avg
- $1,179 / $1,180 / $1,080
- 20-day breakout
- above $1,276 · below $1,131
- ATR(14)
- $35.80 (2.8% a day)
- 52-week range
- $783.85 – $1,293
- Return 3m · 6m · 1y
- +10% · +36% · +57%
What the price could do
| In | Likely range (68%) |
|---|---|
| 1 mo | $1,138 – $1,388 (-9% / +10%) |
| 3 mo | $1,058 – $1,493 (-16% / +19%) |
| 6 mo | $985.64 – $1,603 (-22% / +28%) |
| 1 year | $891.18 – $1,773 (-29% / +41%) |
Analysts (30): buy, mean target $1,328 (+6%)
From its own volatility (34% a year), no drift assumed: what its swings allow, not a forecast.
Eli Lilly news · last two days
News lean: Bullish · 2 up · 1 down- 13h agoWhat Was Eli Lilly Telling You Before Its Stock Ran?Trefis
- 21h agoForget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's Next Leg HigherMotley Fool
- 22h agoA $1,000 Investment in Eli Lilly Became $18,637. The Obesity Boom Changed Everything24/7 Wall St.
- 24h agoEli Lilly’s Growth Is Exceptional. Is Its Valuation Asking Too Much?Insider Monkey
- 25h agoNovo Nordisk and Eli Lilly Just Got Some Fantastic NewsMotley Fool
- 25h agoLilly’s Foundayo Pill Gets European Regulatory Backing – LLY Stock Heads For Best Week In Nearly Four MonthsStocktwits
- 25h agoNovo Nordisk’s Growth Story Is Under Pressure as Eli Lilly Gains GroundInsider Monkey
- 25h agoThe EU’s Drug Regulator Backed Eli Lilly’s Weight-Loss Pill. Here’s What Foundayo Has to Show on October 29TIKR
- 29h agoEli Lilly's Biggest Shareholder Is Selling $347 Million of Stock. Should You Sell Too?Motley Fool
- 29h agoHealth Care Select Sector SPDR (XLV) Adds Eli Lilly and J&J on WednesdayGuruFocus.com
Its order flow and footprint, the AI read of every headline, the expected move, and your own holdings beside it, with your broker connected.
Information and analytics for education only, not investment advice or a recommendation to buy or sell. Alephix Intelligence is not registered with SEBI as an investment adviser or research analyst. Prices may be delayed; figures come from public market data.